Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 48 points (-0.3%) at 17,840 as of Wednesday, Dec. 2, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 879 issues advancing vs. 2,042 declining with 180 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.8%, AstraZeneca ( AZN), down 0.9%, Pfizer ( PFE), down 0.8% and Gilead ( GILD), down 0.7%. Top gainers within the industry include Alkermes ( ALKS), up 2.7%, Incyte ( INCY), up 1.6% and Regeneron Pharmaceuticals ( REGN), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Teva Pharmaceutical Industries is down $1.60 (-2.5%) to $63.42 on heavy volume. Thus far, 3.6 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $63.31-$64.80 after having opened the day at $64.78 as compared to the previous trading day's close of $65.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $54.1 billion and is part of the health care sector. Shares are up 13.1% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Teva Pharmaceutical Industries Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Illumina ( ILMN) is down $2.17 (-1.2%) to $185.24 on light volume. Thus far, 333,847 shares of Illumina exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $184.86-$188.00 after having opened the day at $187.72 as compared to the previous trading day's close of $187.41.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $27.2 billion and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, AbbVie ( ABBV) is down $0.54 (-0.9%) to $58.48 on light volume. Thus far, 2.0 million shares of AbbVie exchanged hands as compared to its average daily volume of 10.6 million shares. The stock has ranged in price between $58.35-$59.39 after having opened the day at $59.18 as compared to the previous trading day's close of $59.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $98.1 billion and is part of the health care sector. Shares are down 9.8% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate AbbVie a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates AbbVie as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).